Top Markets
#1 Cross Cross +12.78%
#2 Casper Network Casper Network +11.85%
#3 Gama Token Gama Token +9.13%
#4 龙虾 (Lobster) 龙虾 (Lobster) +5.14%
#5 Perle Perle +4.54%
#6 Berachain Berachain +4.52%
#7 Akedo Akedo +4.17%
#8 Humanity Humanity +3.77%
#9 The Innovation Game The Innovation Game +3.74%
#10 Palladium Network Palladium Network +3.67%
Coin of the day
Cross Cross
Settings
Language
ENGLISH
Currency
USD
Theme
Accustem Sciences Inc. Accustem Sciences Inc.

Accustem Sciences Inc.

ACUT
Rank in Stocks #36602
AccuStem Sciences, Inc. operates as a life science firm committed to improving... AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer. The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.
Share Price
$0.156
Last synced: 2026-08-13
Market Cap
$2.51M
Change (1 day)
2.97%
Change (1 year)
-91.28%
Country
US
Trade Accustem Sciences Inc. (ACUT)

Category

Healthcare
Revenue for Accustem Sciences Inc. (ACUT)
Revenue in Aug 2026 TTM: 0
According to Accustem Sciences Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Accustem Sciences Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE